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Factors Influencing the Response to High Dose Methotrexate-
based Vincristine and Procarbazine Combination Chemotherapy 
for Primary Central Nervous System Lymphoma
The authors investigated objective response rate to high dose methotrexate (HDMTX)-based 
combination chemotherapy in primary central nervous system lymphoma (PCNSL), and 
sought to identify factors that influence response to HDMTX-based combination therapy. 
Prospective observational analysis was performed on 52 PCNSL patients. All patients 
received HDMTX (3.5 g/m
2) and vincristine (1.4 mg/m
2/day) for one day during weeks 1, 3, 
5, 7, and 9, and procarbazine (100 mg/m
2/day) for one week during weeks 1, 5, and 9. 
Forty-one patients (78.8%) achieved complete or partial remission. Higher objective 
response rates were observed for patients with: 1) age < 60 yr; 2) Eastern Cooperative 
Oncology Group (ECOG) performance score of < 2; 3) low risk status as defined by the 
International Extranodal Lymphoma Study Group; 4) p53 positivity; 5) XBP-1 negativity;  
6) MUM-1 negativity; and 7) homogenous gadolinium enhancement in MR images. 
Multivariate analysis showed that ECOG performance score of < 2, low risk, negativity for 
XBP-1, homogenous gadolinium enhancement by MRI, and response to chemotherapy 
were associated with longer overall survival. In particular, it is interesting to note that 
patients with a PCNSL that is homogenously enhanced by gadolinium have a higher 
objective response rate, and a longer progression-free survival and overall survival.
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INTRODUCTION
Primary central nervous system lymphomas (PCNSLs) are ex-
tranodal malignant lymphomas, which arise within the brain, 
eyes, leptomeninges, or spinal cord in the absence of systemic 
lymphoma at the time of diagnosis. PCNSL accounts for fewer 
than 2% of brain tumors; however, its incidence has increased 
steadily over the last two decades, particularly in immunocom-
petent individuals (1). Today, PCNSL represents 1.8% of all pri-
mary brain tumors in Korea (1). 
  PCNSL is a highly aggressive tumor with a poor prognosis in 
untreated patients (2); however, in contrast to most primary brain 
tumors, PCNSL is sensitive to corticosteroids, chemotherapy, 
and radiotherapy, and durable complete responses and long-
term survival seem possible with these treatments. However, 
the outcome of PCNSL is substantially poorer than that of simi-
lar stage systemic non-Hodgkin’s lymphoma. The combinatori-
al chemotherapeutic regimen of cyclophosphamide, doxorubi-
cin, vincristine, and prednisolone (CHOP) provides the best 
treatment for comparable systemic non-Hodgkin’s lymphoma; 
however, three large, independent, multicenter trials on CHOP 
with cranial irradiation in PCNSL have concluded that they of-
fered no survival advantage over radiotherapy alone (3, 4). The 
apparent inability of these chemotherapeutic regimens to cross 
the brain-blood barrier (BBB) and eradicate microscopic dis-
ease is a major difficulty.
  Radiotherapy alone for PCNSL provides a median survival of 
only 12 to 18 months (5); however, addition of high dose (HD) 
(> 1 g/m
2) methotrexate (MTX)-based chemotherapy to radio-
therapy has been reported to result in substantial improvement 
of median survival time (6-8).
  Present therapeutic knowledge of PCNSL is the result of sev-
eral single-group phase 2 trials, meta-analyses, and large retro-
spective studies. However, to date, only one randomized trial 
has been undertaken, and this was halted prematurely due to 
unsatisfactorily slow accrual (3). The rarity of PCNSL prevents 
randomized trials, and the different opinions expressed on many 
of the therapeutic aspects have resulted in a lack of consensus 
with regard to overall strategy; therefore, the main endpoints 
should be investigated in a randomized setting. In addition, as-
sessments of new first-line chemotherapy combinations in non-
randomized trials, with divergent study designs and entry crite-
ria, do not allow proper comparisons to be made between dif-
ferent regimens, and have resulted in only modest therapeutic Sung KH, et al.  •  Methotrexate Chemotherapy for Primary CNS Lymphoma
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progress (9, 10).
  Despite limited evidence of the efficacies of specific regimens, 
HDMTX chemotherapy followed by whole brain radiotherapy 
(WBRT) is the approach most commonly used for newly diag-
nosed PCNSL (10, 11), and has been reported to result in a 5-yr 
survival of 20%-35% (6, 8, 12-15). MTX is a folate antagonist that 
interrupts DNA synthesis, and is the most widely studied drug 
in the context of PCNSL. 
  Following reports of a better outcome for HDMTX-based com-
bination chemotherapy for PCNSL by the Radiation Therapy 
Oncology Group (RTOG) in the first multicenter trial (8), we 
started HD (3.5 g/m
2/day) MTX-based combination chemother-
apy with vincristine and procarbazine. Although many studies 
have been conducted for identification of the prognostic factors 
of PCNSL, no comprehensive studies have been undertaken to 
identify factors that influence response to HDMTX-based com-
bination chemotherapy. In the present prospective observation-
al study, we investigated objective response rates (ORR) to HD-
MTX-based combination therapy with vincristine and procar-
bazine chemotherapy and progression-free survival (PFS) and 
overall survival (OS) rates after a follow-up period of 2 yr. We 
then sought to identify factors that influence ORR after HDMTX-
based combination chemotherapy for PCNSL.
MATERIALS AND METHODS
Patients
Newly diagnosed immunocompetent patients with PCNSL who 
were registered at our institute from March 2003 to August 2008 
were evaluated for participation in the study. Sixty-one patients 
were diagnosed as CNS lymphoma with histological confirma-
tion. Of these, five refused treatment at our institute, and another 
four did not fulfill the inclusion criteria; 2 had creatinine clear-
ance below 60, 1 had a lymphoma in the chest, and 1 had severe 
thrombocytopenia, which originated from liver cirrhosis. There-
fore, clinical data for 52 patients were available, and these pa-
tients constituted the study cohort. All patients had one or more 
intracranial mass lesions. Histological confirmation of PCNSL 
was required by the following: brain biopsy or resection, CSF 
analysis demonstrating lymphoma cells, or vitrectomy docu-
menting concomitant ocular lymphoma. To exclude evidence 
of systemic lymphoma, a negative staging evaluation by chest, 
abdominal, and pelvic computed tomography (CT) and by bone 
marrow biopsy was required. All patients underwent cranial 
neuroimaging at diagnosis, preferably by MRI. All patients un-
derwent lumbar puncture and a complete ophthalmologic eval-
uation including a slit-lamp examination. 
  Patients with newly diagnosed PCNSL were registered within 
4 weeks of receiving a histological diagnosis and were consid-
ered eligible for enrollment if a pathologic diagnosis had been 
established and all of the following criteria were met: 1) age over 
18 yr; 2) Eastern Cooperative Oncology Group (ECOG) perfor-
mance status grade ≤ 3; 3) negative HIV serology; 4) creatinine 
clearance ≥ 60; 5) no evidence of lymphoma elsewhere in the 
body after CT scans of the chest, abdomen, and pelvis; 6) an ab-
solute neutrophil count of ≥ 2,000 cells/μL and a platelet count 
of ≥ 100,000 cells/μL; and 7) a bilirubin of ≤ 2.0 mg% and a SGOT 
of ≤ 2 times the upper normal limit. The ECOG definition of per-
formance status was used throughout (16). Before chemothera-
py, laboratory diagnosis of Epstein-Barr virus (EBV) infection 
was made on a single serum sample using a standard immuno-
fluorescence test for antibodies to EBV-associated antigens si-
multaneously; immunoglobulin M and G to the viral capsid an-
tigen, the early antigen, and the EBV nuclear antigen.
 
Treatment protocol
Our protocol was modified by the RTOG 93-10 protocol (8). 
Treatment consisted of five cycles of chemotherapy adminis-
tered at fortnight intervals within 5 days intercycle delay, con-
sisting of the following: methotrexate 3.5 g/m
2/day for one day 
during weeks 1, 3, 5, 7, and 9, followed by leucovorin rescue, vin-
cristine (1.4 mg/m
2/day with a cap at 2.0 mg/day) for one day 
during weeks 1, 3, 5, 7, and 9, and procarbazine (100 mg/m
2/day) 
for one week during weeks 1, 5, and 9. Initially, all of the patients 
started to receive intravenous methotrexate at the dose of 3.5 g/
m
2/day. During the cycle of chemotherapy, the dose of metho-
trexate was altered to 3.0 g/m
2/day or 2.5 g/m
2/day when cre-
atine clearance was between 50 and 60, or between 40 and 50, 
respectively. And if creatine clearance fell below 40, we halted 
the schedule and delayed for as long as 2-3 weeks until recovery 
of creatine clearance. Methotrexate (12 mg) was injected into an 
Ommaya reservoir for five cycles on one day during the week 
following each intravenous methotrexate dose. Dexamethasone 
was initiated at a dose of 16 mg/day from the first cycle of HD-
MTX and tapered by 4 mg/day each week, providing that the 
patient’s neurological status remained stable. 
Follow-up
The mean follow-up period was 32.1 months. Repeat neuroim-
aging was required at the completion of neoadjuvant chemo-
therapy and radiotherapy; and then every 2 months for one year, 
every 4 months for the second year, and every 6 months there-
after. A comprehensive review of chemotherapy records was per-
formed for assessment of adherence to the protocol, and a ra-
diologic review was undertaken for assessment of response af-
ter neoadjuvant chemotherapy by two neuroradiologists. MRI 
was performed using a 1.5T clinical scanner (Signa Horizon; GE 
Healthcare, Milwaukee, WI, USA). Basal ganglia, the corpus cal-
losum, brain stem, and cerebellum were defined as deep brain 
structures. Peritumoral edema was categorized as < or ≥ 2 cm 
from the brain tumor as assessed in T2-weighted MR images. 
In cases of multiple brain lesions, regardless of the number of Sung KH, et al.  •  Methotrexate Chemotherapy for Primary CNS Lymphoma
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lesions, different patterns of enhancement between them in MRI 
were counted as heterogeneous enhancement.
Evaluation of response to treatment
Response to treatment was assessed by contrast enhanced brain 
MRI, which was performed at most 7 days before commence-
ment of chemotherapy, after the second and fifth HDMTX che-
motherapy cycles, and 4 weeks after termination of chemother-
apy. National Cancer Institute standardized response criteria 
regarding changes in the size of enhanced lesions on T1 weight-
ed MR images were used to define treatment response (17). In 
brief, complete remission (CR) was defined as the complete dis-
appearance of all evidence of lymphoma; partial response (PR) 
as ≥ 50% decrease in tumor size; progressive disease (PD) as a  
≥ 25% increase in tumor size or the appearance of any new le-
sion; and stable disease (SD) as situations that did not meet any 
of these three previous criteria.
Risk group as defined by the International Extranodal 
Lymphoma Study Group (IELSG)
Using the prognostic scoring system devised by the IELSG, we 
categorized patients into three risk groups, namely, low, inter-
mediate, and high risk groups (18). Variables found to be inde-
pendently associated with survival in the present study were 
used to design a scoring system, as follows. These variables in-
cluded age (≤ or > 60 yr), ECOG performance status grade (0 to 
1 vs 2 to 3), LDH serum level (normal vs elevated), protein con-
centration in CSF (normal vs elevated), and involvement of deep 
brain structures (yes vs no). Each variable was assigned a value 
of 0 if favorable or 1 if unfavorable. Values of these five variables 
were summed for calculation of final risk scores. Patients with 
final risk scores of 0 or 1, 2 or 3, or 4 or 5 were assigned to the 
low, intermediate, or high risk groups, respectively.
Immunohistochemistry and immunofluorescence
Immunohistochemical staining was performed on formalin-
fixed, paraffin-embedded tissues. In addition, MIB-1 (Ki-67) 
staining was performed for evaluation of the proliferative activi-
ties of large neoplastic lymphocytes. Paraffin section immuno-
histochemistry was performed using the avidin-biotin-peroxi-
dase technique after antigen epitope enhancement using a pres-
sure cooker. Final detection was performed by treatment of sec-
tions with diaminobenzidine.
  Anti-BCL-6, anti-p53, and anti-XBP-1 antibodies were pur-
chased from Santa-Cruz Biotechnology (Santa Cruz, CA, USA), 
and monoclonal anti-IL-4 and anti-MUM-1 antibodies were 
purchased from Pharmingen (San Diego, CA, USA). Anti-MUM-1 
antibody was used directly for immunofluorescence staining of 
tumor tissue for flow cytometric analysis (20 µL/10
6 cells).
 
Statistical methods
Objective response (OR) was defined as complete remission or 
partial remission after the fifth course of HDMTX-based com-
bination chemotherapy. OS was calculated from the date of his-
tological diagnosis to death or the last date of follow-up, while 
PFS was calculated from the first day of treatment to relapse or 
progression, or to the last date of follow-up. 
  SPSS version 12.0 (SPSS Institute, Inc., Chicago, IL, USA) was 
used for statistical analyses. Student’s t-test or a nonparametric 
test was used as appropriate for testing of continuous and ordi-
nal variables. Discrete variables were analyzed using Pearson’s 
chi-square test. The cumulative proportions of ORR and their 
95% confidence intervals (CIs), adjusted for a competing event, 
were calculated using the cumulative incidence method devised 
by Prentice et al. (19). Survival curves were drawn using the Ka-
plan-Meier method. The Cox proportional hazards method was 
used for identification of factors associated with ORR. Variables 
found to be significantly associated with ORR by univariate anal-
yses were subjected to multivariate analyses. The Hazard Ratio 
(HR) for overall survival and progression free survival were cal-
culated using a Cox proportional hazards model, with ORR con-
sidered as a time-dependent covariate. Statistical significance 
was accepted for P values of < 0.05. All tests were 2-tailed.
Ethics statement
This study was reviewed and approved by the institutional re-
view board of Masan Samsung Hospital (MSH 2003-014). Writ-
ten informed consent was obtained from all patients who par-
ticipated in this study. 
RESULTS 
Clinical characteristics
Fifty-two patients underwent HDMTX-based combination che-
motherapy for PCNSL. Detailed clinical features in the study are 
listed in Table 1. Mean age of patients at commencement of che-
motherapy was 64.3 yr (range 42-78 yr). Forty-one (78.8%) pa-
tients had an ECOG performance score of < 2 and 11 (21.2%) had 
a score of ≥ 2. Fifteen (28.9%) were categorized as high risk, 19 
(36.5%) as intermediate risk, and 18 (34.6%) as low risk. 
  In histological features, 49 (94.2%) cases were diffuse large B-
cell lymphoma, 1 (1.9%) case was anaplastic large B-cell lym-
phoma, and 2 (3.8%) cases were marginal zone B-cell lympho-
ma. In terms of MRI findings, homogeneous gadolinium en-
hancement was observed for 31 (59.6%) tumors and heteroge-
neous enhancement for 21 (40.4%).
  Five cycles of HDMTX-based combination chemotherapy 
were administered to all patients. No dose-reduction was per-
formed during the first cycle. However, during the second and 
third cycles, one patient received MTX at 3.0 g/m
2/day, during 
the fourth cycle, 1 patient received MTX at 2.5 g/m
2/day, and 3 Sung KH, et al.  •  Methotrexate Chemotherapy for Primary CNS Lymphoma
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patients received MTX at 3.0 g/m
2/day; and during the fifth cy-
cle, 2 patients received MTX at 2.5 g/m
2/day and 5 at 3.0 g/m
2/
day.
Response to high dose methotrexate-based combination 
chemotherapy
The overall crude incidence of objective response to HDMTX 
chemotherapy was 78.8% (CR of 63.5% and PR of 15.3%), and 
the overall incidence after adjusting for competing events was 
82.4% (95% CI, 75.3%-89.5%). The ORR was 94.1% for patients 
aged < 60 yr and 71.4% for those aged ≥ 60 yr, which was a sig-
nificant difference (P = 0.034). In patients with an ECOG per-
formance score of < 2, the ORR was 87.8%, and in those with an 
ECOG performance score of ≥ 2, the ORR was 45.5% (P < 0.001). 
ORRs of patients in the high, intermediate, and low risk groups 
were 46.7%, 89.5%, and 94.4%, respectively (P < 0.001). Howev-
er, no significant ORR differences were found for the other clini-
cal variables studied. Table 2 details the clinical variables sub-
jected to univariate analysis. A younger age (< 60 yr), a good per-
formance status (ECOG performance score < 2), and a low risk 
were found to be associated with a significantly higher ORR. 
  In terms of the features of brain tumors, ORR was 91.7% for 
patients positive for p53 expression, and 50.0% for those nega-
tive for p53 (P = 0.026). Those positive for XBP-1 had an ORR of 
53.8%, and those negative for XBP-1 an ORR of 87.2% (P = 0.017), 
and those positive for MUM-1 had an ORR of 64.0%, and those 
negative for MUM-1 an ORR of 92.6% (P = 0.032). Patients with 
heterogeneous gadolinium enhancement in MR images had an 
objective response of 61.9%; however, those with homogeneous 
enhancement had an objective response of 90.3% (P < 0.001). 
We found no other variable with a significant effect on ORR. The 
crude ORRs of tumors that were heterogeneously or homoge-
neously enhanced were 61.9% and 90.3%, and ORRs after adjust-
ing for competing events were 63.4% (95% CI, 56.6%-70.2%) 
and 88.8% (95% CI, 81.9%-95.7%), respectively. This finding 
confirms that an enhancing pattern independently predicts ob-
jective response to HDMTX chemotherapy.
Characteristics No. of 
patients
% of  
number
Age (yr)
   Mean
   Range
   < 60
   ≥ 60
 
64.4
42-78
17
35
 
(-)
(-)
32.7
67.3
Gender
   Male
   Female
 
30
22
 
57.7
42.3
ECOG performance score
   < 2
   ≥ 2
 
41
11
 
78.8
21.2
CSF metastasis
   Yes
   No
 
  8
44
 
15.4
84.6
Elevated CSF protein 
   Yes
   No
 
33
19
 
63.5
36.5
Elevated serum LDH
   Yes
   No
 
16
36
 
30.8
69.2
Risk of international extranodal lymphoma study group
   High
   Intermediate
   Low
 
15
19
18
 
28.9
36.5
34.6
Ocular involvement
   Yes
   No
 
  4
48
 
  7.7
92.3
Epstein-Barr virus infection
   Yes
   No
 
46
  6
 
88.5
11.5
Surgical intervention
   Resection
   Biopsy
 
  9
43
 
17.3
82.7
Histopathological feature
   Diffuse large B cell lymphoma
   Anaplastic large B cell lymphoma
   Marginal zone B cell lymphoma
 
49
  1
  2
 
94.2
  1.9
  3.9
Characteristics No. of 
patients
% of  
number
BCL-6
   Positive
   Negative
 
39
13
 
75.0
25.0
p53
   Positive
   Negative
 
36
16
 
69.2
30.8
IL-4
   Positive
   Negative
 
15
37
 
28.8
71.2
XBP-1
   Positive
   Negative
 
13
39
 
25.0
75.0
MUM-1
   Positive
   Negative
 
25
27
 
48.1
51.9
Necrosis
   Positive
   Negative
 
41
11
 
78.8
21.2
Ki-67 (%)
   < 50
   ≥ 50
 
18
34
 
34.6
65.4
Involvement of deep location 
   Yes
   No
 
20
32
 
38.5
61.5
Distance of peritumoral edema from tumor (cm)
   < 2 
   ≥ 2 
 
19
33
 
36.5
63.5
Number of brain lesion
   Single
   Multiple 
 
38
14
 
73.1
26.9
Gadolinium enhancement in MRI
   Homogeneous
   Heterogeneous 
31
21
59.6
40.4
Table 1. Clinical characteristics of patients who underwent the high dose methotrexate based-combination chemotherapy for primary central nervous system lymphoma (n = 52)Sung KH, et al.  •  Methotrexate Chemotherapy for Primary CNS Lymphoma
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Progression free survival and overall survival
Table 3 illustrates median PFSs and median OSs of all 52 study 
subjects. Median PFS was 20.8 months (95% CI, 16.2-24.8 months). 
Median PFS was 21.7 months for those < 60 yr and 18.1 months 
for those ≥ 60 yr (P = 0.046). Patients with an ECOG performance 
score of < 2 had a median PFS of 23.2 months, and those with 
an ECOG performance score of ≥ 2 had a median PFS of 13.6 
months (P = 0.018). Median PFSs in the high, intermediate, and 
low risk groups were 15.4, 18.8, and 29.4 months, respectively (P 
= 0.006). In terms of features of brain tumors, median PFS was 
21.7 months for patients positive for p53 expression, and 18.4 
months for patients negative for p53 (P = 0.044). Patients nega-
tive for XBP-1 had a greater median PFS than those positive for 
XBP-1 (27.4 months vs 13.6 months, respectively; P = 0.028). Pa-
tients positive for MUM-1 had a median PFS of 18.3 months, and 
those negative for MUM-1 had a median PFS of 23.2 months (P 
= 0.002). Of particular interest, median PFS was 17.8 months for 
patients with a heterogeneously gadolinium enhanced PCNSL, 
and 30.6 months for those with a homogeneous enhanced PCNSL 
(P < 0.001). Fig. 1 shows the progression-free survival curve for 
homogeneously vs heterogeneously enhanced PCNSL.
  Median OS and the 2-yr survival rate were 30.5 months (95% 
CI, 21.7-39.3 months) and 62.3%. Furthermore, median OS was 
36.7 months in patients with an ECOG performance score of < 2 
and 21.2 months in those with a performance score of ≥ 2 (P = 
0.021). Patients in the high, intermediate, and low risk groups 
had OSs of 19.5, 29.6, and 42.6 months, respectively, and these 
were significantly different (P < 0.001). As expected, patients who 
achieved an objective response to HDMTX based combination 
chemotherapy survived longer. The median OS of patients who 
experienced an objective response was 35.4 months, whereas 
the median OS of patients who did not experience an objective 
response was 12.7 months (P < 0.001). In terms of features of 
brain tumor, the median OS was 36.7 months in patients posi-
tive for p53, and 25.3 months in those negative for p53 (P = 0.048). 
Positivity and negativity for XBP-1 expression were found to be 
associated with median OSs of 17.8 and 34.2 months, respective-
ly (P = 0.004). Of particular interest, homogeneous gadolinium 
enhancement was found to be associated with longer median 
OS (38.5 months vs 24.6 months, P < 0.001). Fig. 2 shows the 
Characteristics No.   CR + PR  
  (n = 41)
  SD + PD  
  (n = 11) P value
Age (yr)
   < 60 
   ≥ 60 
 
17
35
  
16 (94.1%)
25 (71.4%)
 
1 (5.9%)
10 (28.6%)
 0.034
Gender
   Male
   Female
 
30
22
 
23 (76.7%)
18 (81.8%)
 
7 (23.3%)
4 (18.2%)
 0.844
ECOG performance score
   < 2
   ≥ 2
 
41
11
 
36 (87.8%)
5 (45.5%)
 
5 (12.2%)
6 (54.5%)
< 0.001
CSF metastasis
   Yes
   No
 
  8
44
 
6 (75.0%)
35 (79.5%)
 
2 (25.0%)
9 (20.5%)
0.924
Elevated CSF protein 
   Yes
   No
 
33
19
 
26 (78.8%)
15 (78.9%)
 
7 (11.2%)
4 (11.1%)
 0.980
Elevated serum LDH
   Yes
   No
16
36
 
12 (75.0%)
29 (80.6%)
 
4 (25.0%)
7 (19.4%)
 0.843
Risk of international extranodal  
  lymphoma study group
   High
   Intermediate 
   Low
15
19
18
 
7 (46.7%)
17 (89.5%)
17 (94.4%)
 
8 (53.3%)
2 (10.5%)
1 (5.6%)
 < 0.001
Ocular involvement
   Yes
   No
 
  4
48
 
3 (75.0%)
40 (83.3%)
 
1 (25.0%)
8 (16.7%)
 0.483
Epstein-Barr virus infection
   Yes
   No
 
46
  6
 
36 (78.3%)
5 (83.3%)
 
9 (21.7%)
1 (16.7%)
 0.358
Surgical intervention
   Resection
   Biopsy
 
  9
43
 
7 (77.8%)
34 (79.1%)
 
2 (22.2%)
9 (20.9%)
 0.864
Histopathological feature
   Diffuse large B cell lymphoma
   Others
 
49
  3
 
40 (81.6%)
2 (66.7%)
 
10 (18.4%)
1 (33.3%)
 0.255
Table 2. Response to the high dose methotrexate based combination chemotherapy in patients with primary central nervous system lymphoma (n = 52)
Characteristics No.   CR + PR  
  (n = 41)
  SD + PD  
  (n = 11) P value
BCL-6
   Positive
   Negative
 
39
13
 
31 (79.5%)
10 (76.9%)
 
8 (20.5%)
3 (23.1%)
 0.868
p53
   Positive
   Negative
  
36
16
  
33 (91.7%)
8 (50.0%)
  
3 (8.3%)
8 (50.0%)
  0.026
Interleukin-4
   Positive
   Negative
 
15
37
 
11 (73.3%)
30 (81.1%)
 
4 (26.7%)
7 (18.9%)
 0.408
XBP-1
   Positive
   Negative
 
13
39
 
7 (53.8%)
34 (87.2%)
6 (46.2%)
5 (12.8%)
 0.017
MUM-1
   Positive
   Negative
 
25
27
 
16 (64.0%)
25 (92.6%)
 
9 (36.0%)
2 (7.4%)
 0.032
Necrosis
   Positive
   Negative
 
41
11
 
31 (75.6%)
10 (90.9%)
 
10 (24.6%)
1 (9.1%)
 0.261
Ki-67 (%)
   < 50
   ≥ 50
 
18
34
 
13 (72.2%)
28 (82.4%)
 
5 (27.8%)
6 (17.6%)
 0.623
Involvement of deep location 
   Yes
   No
 
20
32
 
16 (80.0%)
25 (78.1%)
 
4 (20.0%)
7 (21.9%)
 0.920
 
Distance of peritumoral edema  
  from tumor (cm)
   < 2 
   ≥ 2 
 
19
33
 
14 (73.7%)
27 (81.8%)
 
5 (26.3%)
6 (18.2%)
 0.849
Number of brain lesion
   Single 
   Multiple
 
38
14
 
30 (78.9%)
11 (78.6%)
 
8 (21.1%)
3 (214%)
 0.584
Gadolinium enhancement in MRI
   Homogeneous
   Heterogeneous 
 
31
21
 
28 (90.3%)
13 (61.9%) 
 
3 (9.7%)
8 (38.1%)
  < 0.001Sung KH, et al.  •  Methotrexate Chemotherapy for Primary CNS Lymphoma
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Kaplan-Meier survival curves of patients for homogeneously vs 
heterogeneously enhanced PCNSL.
Multivariate analysis of factors that influence progression 
free and overall survival
In terms of PFS, seven factors, namely, age, ECOG performance 
score, risk of IELSG, p53, XBP-1, and MUM-1 expression, and 
gadolinium enhancement were found to be positively associat-
ed with PFS by univariate analysis (Table 2). After multifactor 
adjustment, the HR of an ECOG performance of < 2 over a per-
formance of ≥ 2 for longer PFS was 2.68 (95% CI, 1.50-3.86; P = 
0.037). The HR of high risk over low risk, according to the IELSG, 
for longer PFS was 3.03 (95% CI, 1.54-4.37; P = 0.019). The HR of 
negativity over positivity for XBP-1 for longer PFS was 2.64 (95% 
CI, 1.46-3.52; P = 0.042), and the HR of negativity over positivity 
for MUM-1 for longer PFS was 2.93 (95% CI, 1.68-3.72; P = 0.035). 
Finally, the HR of homogeneous over heterogeneous gadolini-
um enhancement for longer PFS was 3.32 (95% CI, 1.90-4.54; P 
= 0.002). However, multivariate analysis showed that a younger 
age and p53 expression were not associated with longer PFS.
  In terms of OS, 6 factors, namely, ECOG performance score, 
risk of IELSG, response to HDMTX based chemotherapy, ex-
pression of p53 and XBP-1, and gadolinium enhancement pat-
tern were found to be significantly associated with longer OS by 
univariate analysis (Table 2). After multifactor adjustment, the 
HR of an ECOG performance score of < 2 over a score of ≥ 2 for 
longer OS was 2.53 (95% CI, 1.33-3.62; P = 0.040), the HRs of a 
high risk over intermediate risk, a high risk over a low risk, and 
an intermediate risk over a low risk were 2.44 (95% CI, 1.71-3.25; 
P = 0.048), 4.35 (95% CI, 2.70-6.23; P < 0.001), and 2.52 (95% CI, 
1.58-3.41; P = 0.045), respectively. The HR of negativity over pos-
itivity for XBP-1 expression for longer OS was 3.01 (95% CI, 1.59-
4.44; P = 0.022), the HR of homogenous over heterogeneous en-
hanced PCNSL for longer OS was 4.18 (95% CI, 2.26-4.90; P < 
Table 3. Progression-free survivals and overall survival (n = 52)
Characteristics
Median 
progression 
free 
survival 
(month)
P value
Median 
overall 
survival 
(month)
P value
Age (yr)
   < 60 
   ≥ 60 
 
21.7
18.1
0.046  
32.3
27.3
 0.128
Gender
   Male
   Female
 
19.8
21.1
 0.856  
28.0
31.3
 0.541
ECOG performance status
   < 2
   ≥ 2
 
23.2
13.6
0.018  
36.7
21.2
 0.021
CSF metastasis
   Yes
   No
 
19.4
20.8
0.903  
28.0
32.3
 0.284
Elevated CSF protein 
   Yes
   No
20.1
20.8
0.952
 
27.8
31.3
 0.373
Elevated serum LDH
   Yes
   No
 
18.8
21.1
 0.351  
30.2
34.0
 0.687
Risk of international extranodal  
  lymphoma study group
   High
   Intermediate 
   Low
 
15.4
18.8
29.4
 0.006  
19.5
29.6
42.6
 < 0.001
Ocular involvement
   Yes
   No
 
19.4
20.8
 0.922  
31.3
30.2
 0.916
Surgical intervention
   Resection
   Biopsy
 
19.8
20.5
0.827  
32.3
30.2
0.864
Response to MTX based   
  combination chemotherapy
   CR + PR
   SD + PD
 
20.4
2.1
< 0.001  
35.4
12.7
< 0.001
Histopathological feature
   Diffuse large B cell lymphoma
   Others
 
20.2
20.5
0.988  
30.2
31.3
0.827
Characteristics
Median 
progression 
free 
survival 
(month)
P value
Median 
overall 
survival 
(month)
P value
BCL-6
   Positive
   Negative
 
20.8
19.4
0.763  
31.0
27.5
0.719
p53
   Positive
   Negative
 
21.7
18.4
0.044  
36.7
25.3
0.048
IL-4
   Positive
   Negative
 
19.8
20.5
0.688  
27.8
34.0
0.167
XBP-1
   Positive
   Negative
 
13.6
27.4
0.028  
17.8
34.2
0.004
MUM-1
   Positive
   Negative
 
18.3
23.2
0.002  
28.0
31.3
0.849
Necrosis
   Positive
   Negative
 
19.4
20.5
0.754  
28.0
31.0
0.911
Ki-67 (%)
   < 50
   ≥ 50
 
18.8
20.8
0.620  
27.8
31.3
0.776
Involvement of deep location 
   Yes
   No
 
19.0
22.6
0.534  
30.2
34.0
0.639
Distance of peritumoral edema 
from tumor (cm)
   < 2 
   ≥ 2 
 
21.1
19.8
0.757  
27.5
32.3
0.301
Number of brain lesion
   Single
   Multiple 
 
21.4
19.2
0.668  
31.2
28.6
0.528
Gadolinium enhancement in MRI
   Homogeneous
   Heterogeneous 
30.6
17.8
< 0.001  
38.5
24.6
< 0.001Sung KH, et al.  •  Methotrexate Chemotherapy for Primary CNS Lymphoma
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0.001), and the HR of the presence over the absence of an ob-
jective response to HDMTX chemotherapy for longer OS was 
5.22 (95% CI, 2.84-7.60; P < 0.001). Although p53 expression was 
found to be associated with longer OS by univariate analysis, 
multivariate analysis revealed no significant association. 
Mortality and recurrence
During the follow-up period, thirty-seven (71.2%) patients died. 
Of these, four patients (7.7%) died during treatments: 2 patients 
succumbed to disease progression; 1 to acute renal failure; and 
1 to sepsis. In patients of diseases progression, acute cerebral 
edema and hydrocephalic crisis were the cause of death. Acute 
renal failure and sepsis were attributed to toxicity of HDMTX-
based combination chemotherapy. And, three patients were 
above 60 yr old. There were no deaths from other systemic dis-
ease, such as acute myocardiac infarction, pulmonary embo-
lism, complication of diabetes, etc.
  Forty patients (76.9%) experienced disease recurrence. Me-
dian time to recurrence was 8.3 months (range, 2.4-45.3 months). 
After recurrence, 27 patients (67.5%) were treated with HDMTX-
based combination chemotherapy again, and 13 patients (32.5%) 
were treated with WBRT.
DISCUSSION
Although many reports have shown that several factors influ-
ence the prognosis of PCNSL, no study to date has assessed the 
factors that influence objective response to HDMTX based com-
bination chemotherapy for PCNSL. In particular, there has been 
no study to report on the relationship between gadolinium en-
hancement in MRI and outcome of HDMTX for PCNSL. Ferreri 
et al. suggested that age, performance status, LDH serum level, 
HDMTX, and the use of HD cytarabine are significantly associ-
ated with overall response rate (18). Their therapeutic modali-
ties included radiotherapy alone, radiotherapy followed by che-
motherapy, chemotherapy alone, and chemotherapy followed 
by radiotherapy. However, their chemotherapeutic regimen was 
highly heterogeneous, that is, it involved MTX followed by alkyl-
ating agents, HD cytarabine, and anthracycline. Other regimens 
included alkylating agent alone, the CHOP regimen, an HD cy-
tarabine-based regimen, HDMTX alone, HDMTX plus alkylat-
ing agents, HDMTX plus CHOP-like regimens, and others. Fur-
thermore, it has not been previously reported that the molecu-
lar features of PCNSL can influence objective response to HD-
MTX-based combination chemotherapy.
  Of particular interest, the present study shows that patterns of 
gadolinium enhancement were predictive of response to HDMTX. 
According to a report by Algazi et al. (20), contrast enhancement 
was uniform in 55% to 60% of PCNSL cases. They suggested that 
the apparent diffusion coefficient (ADC) is correlated with cel-
lular density in PCNSL, and that pre-therapeutic ADC (a possi-
ble surrogate marker of cellular density) is predictive of clinical 
outcome. Low cellularity, which reduces ADC within contrast-
enhancing regions, may permit a high influx of contrast into the 
tumor; therefore, PCNSLs showing homogeneous gadolinium 
enhancement have lower cellularity and a higher objective re-
sponse due to the smaller tumor cell burden. Unfortunately, 
because ADC mapping was not performed on many of the MR 
images, we are unable to present the association between ADC 
and response to HDMTX-based combination chemotherapy.
  Although many other characteristics were not found to affect 
objective response to HDMTX-based combination chemother-
apy, we found that age, performance status, and low risk status 
as defined by the IELSG, expression of p53, XBP-1, and MUM-1, 
and patterns of gadolinium enhancement in MR images signifi-
cantly affected objective response. Findings by Ferreri et al. (21) 
who also studied predictors of treatment outcome in PCNSL, 
concur with those of the present study, namely, that age, perfor-
mance status, and a lower prognostic score (as defined by the 
IELSG) influence overall response rate to HDMTX-based com-
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Fig. 1. Progression-free survival curves for the patients with homogeneously versus 
heterogeneously enhanced primary central nervous system lymphoma. 
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Fig. 2. Kaplan-Meier survival curves for the patients with homogeneously versus 
heterogeneously enhanced primary central nervous system lymphoma.
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bination chemotherapy. However, in the present study, unlike 
the previous study, multivariate analysis showed no relationship 
between age and longer PFS or OS; the cause of this discrepan-
cy is not known. 
  Rubenstein et al. (22) suggested that several clinical features 
of PCNSL exhibit a distinct biologic phenotype; that is, 1) a short 
response duration to a combined modality therapy; 2) a unique 
proclivity to grow in the CNS; and 3) a heightened responsive-
ness to MTX. In terms of prognostic significance in correlation 
with biologic phenotype, diffuse large B-cell lymphoma (DLBCL) 
cases with germinal center B-cell patterns expressing BCL-6 have 
been known to show a much better prognosis than DLBCL cases 
with activated B-cell expressing MUM-1 (22, 23). However, other 
groups observed no difference in survival between DLBCL pa-
tients based on BCL-6 expression (24, 25). One reverse report 
showed that BCL-6 expression indicates poor prognosis (26). In 
our study, BCL-6 expression was not associated with PFS and 
OS, and negative expression of MUM-1 was associated with lon-
ger PFS in multivariate analysis. And, this multivariate analysis 
showed that negative expression of XBP-1 was associated with 
longer PFS and OS. Rubenstein et al. (22) also suggested that 
XBP-1 was among the genes showing the most significant dif-
ferential expression in PCNSL, and that the strongest XBP-1 pro-
tein expression among dense tumor cell populations was asso-
ciated with the vasculature. Further studies are needed to de-
termine the role of these biomarkers.
  Although the present study shows that several factors, includ-
ing age < 60 yr, good performance status, low risk status of IELSG, 
expression of p53, XBP-1, and MUM-1, and homogeneous MRI 
enhancement patterns, are associated with objective response 
to HDMTX-based combination chemotherapy for PCNSL, sev-
eral study shortcomings limit our conclusions. 
  First, HDMTX is known to be the primary treatment for PCNSL 
and has been successfully incorporated into multi-drug chemo-
therapy regimens, which has in turn been associated with nota-
ble improvements in response and survival. The authors com-
menced this 6-yr long study in 2003; thus, the study is somewhat 
dated in terms of current practice. In fact, results of combination 
chemotherapies with other drugs, such as, high-dose cytarabine 
(21), temozolomide (27), and cyclophosphamide (28) have also 
been reported. In addition, the recently introduced extremely 
high dose MTX mono-chemotherapy (> 8 g/m
2/day) (29), and 
development of targeted drugs, such as, rituximab (15), may have 
improved the prognosis for PCNSL. Second, samples were ex-
amined as paraffin-embedded tissues and we did not investi-
gate genetic alterations in proteins, which have previously been 
found to be associated with response to treatment. Therefore, 
the present study does not shed light on pathophysiologic mech-
anisms. Third, we did not perform ADC mapping using MR im-
ages during the early period of this study in most patients, which 
would have possibly confirmed the existence of a positive asso-
ciation between homogeneous gadolinium enhancement and 
high signal intensity of the ADC map. Therefore, we could not 
examine the association between homogeneous enhancement 
and low cellularity of tumor. Accordingly, we did not present any 
confirmative association between responsiveness to HDMTX 
chemotherapy and low cellularity of PCNCL. Fourth, the num-
ber of patients in this study was relatively small. Therefore, we 
need to perform a randomized and prospective study of more 
patients in order to obtain stronger evidence to support the re-
sults of this study.
  In conclusion, through prospective analysis, we suggest that 
an age of < 60 yr, an ECOG performance score of < 2, a low or in-
termediate risk status of IELSG, positivity for p53, negativity for 
XBP-1 or MUM-1, and homogenous gadolinium enhancement 
in MRI should be associated with a good response of PCNSL to 
HDMTX-based combination chemotherapy. In particular, it was 
interesting to note that patients with a PCNSL that is homoge-
neously enhanced by gadolinium have a higher ORR to HDMTX-
based chemotherapy, and a longer PFS and OS, as well as bet-
ter response to HDMTX-based chemotherapy.
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Factors Influencing the Response to High Dose Methotrexate-based Vincristine and 
Procarbazine Combination Chemotherapy for Primary Central Nervous System 
Lymphoma
Kang Hyun Sung, Eun Hee Lee, and Young Zoon Kim
Prospective observational analysis was performed on 52 primary central nervous system lymphoma (PCNSL) patients. All patients 
received HDMTX, vincristine, and procarbazine. Forty-one patients (78.8%) achieved complete or partial remission after the 
combination chemotherapy. Higher OR rates were observed in the patients with: 1) age < 60 yr; 2) ECOG performance score of  
< 2; 3) low risk status as defined by the International Extranodal Lymphoma Study Group (IELSG); 4) p53 positivity; 5) XBP-1 
negativity; 6) MUM-1 negativity; and 7) homogenous gadolinium enhancement in MR images. Multivariate analysis showed that 
ECOG performance score of < 2, low risk, negativity for XBP-1, homogenous gadolinium enhancement by MRI, and response to 
chemotherapy were associated with longer OS.